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IS RESTAGING TRANSURETHRAL RESECTION (TUR)
NECESSARY IN PATIENTS WITH NON-MUSCLE INVASIVE
BLADDER CANCER (NMIBC) AND FOCAL LAMINA
PROPRIA INVASION?François AUDENET*, Caitlyn RETINGER, Christine CHIEN,
Nicole BENFANTE, Bernard BOCHNER, Machele DONAT,
Harry HERR, Guido DALBAGNI, New York, NY
INTRODUCTION AND OBJECTIVES: Repeat TUR is both
diagnostic and therapeutic in patients with T1 NMIBC. The depth of
lamina propria invasion was shown to have the largest impact on T1
tumors prognosis. We intended to evaluate the inﬂuence of lamina
propria invasion type at initial TUR on the re-staging pathology.
METHODS: We reviewed from our prospectively maintained
database all patients with a high-grade pT1 disease who underwent a
re-staging TUR within 6 weeks at our center from January 2015 to May
2016. All pathology specimens were reviewed by a dedicated uro-
pathologist. The characteristics of the lamina propria invasion were
assessed according to the pathological report to identify focal invasion.
The pathology of the second TUR was analyzed regarding the char-
acteristics of the initial resection.
RESULTS: We included 198 patients, with a median age of 70
years (interquartile range: 63-79). Muscle was present in the initial TUR
specimen in 107 patients (54%). Pathology restaging was pT0 in 73
patients (37%), pTis in 44 (22%), pTa in 27 (14%), pT1 in 50 (25%) and
pT2 in 4 (2%). Eighty-seven patients (44%) had tumors with minimal
lamina propria invasion at initial TUR (53 specimens (27%) with focal
invasion, 15 (7.6%) with superﬁcial invasion and 19 (10%) with multi-
focal superﬁcial invasion). Focal invasion was deﬁned as few malignant
cells in the lamina propria, superﬁcial invasion as T1a and multifocal
superﬁcial invasion as multiple areas of T1a. Of the patients with min-
imal lamina propria invasion, residual disease was found in 20 patients
(23%). However, none of those patients had T2 disease (Table 1).
CONCLUSIONS: A signiﬁcant number of patients with T1 tu-
mors have residual disease at restaging TUR. This is not any different
among patients with minimal lamina propria invasion. All patients with
T1 tumors should undergo restaging TUR irrespective of the depth of
penetration into the lamina propria.
Source of Funding: NonePD48-02
THE EFFECT OF IMMEDIATE SECOND RESECTION OF
TUMOR BED AFTER COMPLETE TRANSURETHRAL
RESECTION OF BLADDER TUMOR : A COMPARATIVE
STUDY USING PROPENSITY SCORE MATCHINGMyungchan Park*, Sang Hyun Park, Busan, Korea, Republic of;
Myung Kim, Jong Keun Kim, Cheryn Song, Bumsik Hong, Hanjong Ahn,
Seoul, Korea, Republic ofINTRODUCTION AND OBJECTIVES: This study aimed to
evaluate the immediate second resection of tumor bed after complete
transurethral resection (TUR) could improve the quality of the initial TUR.
METHODS: We retrospectively collected the data from 304
patients (immediate second resection group; ISR group) who had un-
derwent immediate second resection as previously reported (Kim et al.
J Endourol 2008) and 232 patients (non-second resection group; NSR
group) who had not undergone immediate second resection by other
surgeon. Confounding variables including age, gender, multiplicity of
tumor, tumor size, pathologic tumor stage, pathologic tumor grade were
matched in the two study groups using propensity score matching.
RESULTS: The propensity score matched model included 6
variables, and matching by propensity score yielded 170 patients in ISR
group matched to 170 patients in NSR group. (ISR group; 97 Ta, 6 CIS
and 67 T1, NSR group; 94 Ta, 7 CIS and 69 T1). Of the patients who
received restaging TUR (ISR group; 46 vs. NSR group; 39), the
absence of residual tumors was signiﬁcantly greater in ISR group than
NSR group (74.3% vs. 47.8%, p¼0.002). Among the patients with non-
muscle invasive bladder tumor, ISR group demonstrated signiﬁcantly
better outcomes compared to NSR group in terms of 2-year RFS
(82.9% vs.66.1%, p<0.001). The patient with high risk disease showed
that the 2-year RFS was better for those who underwent immediate
second resection than those who did not (83.7% vs. 56.6. p<0.001).
CONCLUSIONS: After controlling for variables affecting dis-
ease recurrence, the immediate second resection of tumor bed after
complete TUR of bladder tumor improved recurrence free survival in
patients with non-muscle invasive bladder tumor.
Source of Funding: NonePD48-03
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INTRODUCTION AND OBJECTIVES: Goals of transurethral
resection of a bladder tumour (TUR) are to completely resect the lesions
and to make a correct diagnosis in order to adequately stage the pa-
tient. It is well known that the presence of detrusor muscle in the
specimen is a prerequisite to minimize the risk of under staging.
Persistent disease after resection of bladder tumours is not uncommon
and is the reason why the European Guidelines recommended a re-
TUR for all T1 tumours. It was recently published that when there is
muscle in the specimen, re-TUR does not inﬂuence progression or
cancer speciﬁc survival. We present here the patient and tumour factors
that may inﬂuence the presence of residual disease at re-TUR.
METHODS: In our retrospective cohort of 2451 primary T1G3
patients initially treated with BCG, pathology results for 934 patients
(38.1%) who underwent re-TUR are available. 75.4% had multifocal
tumours, 42.7% of tumours were more than 3 cm in diameter and 25.8%
had concomitant CIS. We analyse this subgroup of patients who un-
derwent re-TUR: there was no residual disease in 267 patients (28.6%)
and residual disease in 667 patients (71.4%): Ta in 378 (40.5%) and T1
in 289 (30.9%) patients. Age, gender, tumour status (primary/recurrent),
previous intravesical therapy, tumour size, tumour multi-focality,
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lysed in order to evaluate risk factors of residual disease at re-TUR,
both in univariate analyses and multivariate logistic regressions.
RESULTS: The following were not risk factors for residual dis-
ease: age, gender, tumour status and previous intravesical chemo-
therapy. The following were univariate risk factors for presence of
residual disease: no muscle in TUR, multiple tumours, tumours > 3 cm,
and presence of concomitant CISDue to the correlation between tumor
multi-focality and tumor size, the multivariate model retained either the
number of tumors or the tumor diameter (but not both), p < 0.001. The
presence of muscle in the specimen was no longer signiﬁcant, p ¼ 0.15,
while the presence of CIS only remained signiﬁcant in the model with
tumor size, p < 0.001.
CONCLUSIONS: The most signiﬁcant factors for a higher risk of
residual disease at re-TUR in T1G3 patients are multifocal tumours and
tumoursmore than 3 cm. Patients with concomitant CIS and thosewithout
muscle in the specimen also have a higher risk of residual disease.
Source of Funding: NonePD48-04
CLINICAL BENEFITS OF COMBINED TECHNIQUE
TRANSURETHRAL EN-BLOC + ENDOSCOPIC MUCOSAL
RESECTION FOR NON-MUSCLE INVASIVE BLADDER
CANCER, ESPECIALLY IN LARGE TUMOR.Yasushi Hayashida*, Ureshino, Japan; Yasuyoshi Miyata,
Tomohiro Matsuo, Nagasaki, Japan; Keisuke Taniguchi, Ureshino,
Japan; Hideki Sakai, Nagasaki, Japan
INTRODUCTION AND OBJECTIVES: Transurethral resection
(TUR) is standard therapy for non-muscle invasive bladder cancer
(NMIBC). Radical resection is an important predictor for outcome, and
accurate pathological diagnosis is the key determinant factor to decide
treatment strategy after TUR. In short, TUR are expected to complete
excision and accurate pathological diagnosis for improved the prog-
nosis in patients with NMIBC. Although TUR methods are established,
pathological diagnosis is difﬁcult because of heat denaturation and burn
mark. In recent years, transurethral En-bloc resection technique is re-
ported to be useful for judging cancer invasion in NMIBC. However,
such method has disadvantage in prolongation of surgical time,
particularly in large tumors. In this study, we investigated the usefulness
and safety of combination therapy of electrical En-bloc resection and
endoscopic mucosal resection (En-bloc + EMR) in NMIBC patients.
METHODS: We analyzed 30 patients who were clinically diag-
nosed with NMIBC. The median of the tumour diameter was 30 (15e55)
mm. At ﬁrst, a tumour mass was cut by using CAPTIVATOR II (Boston
Scientiﬁc) in the same way as EMR. Subsequently, a circular incision was
created around the residual tumour, maintaining a distance of approxi-
mately 5e10mm from the tumour edge, for the En-bloc resection. For the
control, TUR was performed in 16 patients that were matched for tumour
diameter and clinical stage. All surgeries were performed by one urologist.
Before the patients were enrolled, the institutional ethical committee
approved the study, and written informed consent was obtained.
RESULTS: The mean operation time for EMR and En-bloc
resection was 1.2 and 13.9 min respectively and total operation time
was 15.0 min. That was similar to that for TUR (P ¼ 0.94, mean ¼ 16.2
and SD ¼ 3.8 min). One patients had mild perforation of the bladder.
However, no severe complications were observed and no signiﬁcant
difference was found regarding periods of catheterization and hospi-
talization. The pathologists can diagnose the invasion status with
considerable certainty in all specimens obtained by En-bloc + EMR,
compared to by TUR because of less heat denaturation and burn mark.
CONCLUSIONS: Our results showed En-bloc + EMR technique
is a useful and safe. We believe that this technique is particularly
suitable for large tumors because control of bleeding and visual ﬁeld are
clearly better than TUR. In addition, this technique has an advantage in
accurate pathological diagnosis to distinguish pTa and pT1.
Source of Funding: None.PD48-05
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INTRODUCTION AND OBJECTIVES: Management of T1
bladder cancer (BC) is controversial and reliable prognostics are
urgently needed. We evaluated the clinical impact of two systems to
sub-stage T1-BC on a large series of T1-BC patients treated with
Bacillus Calmette-Guerin (BCG).
METHODS: We included 601 patients with primary (ﬁrst tumor)
T1-BC, who were treated with at least one induction schedule of BCG
instillations and followed in four university hospitals. The slides were
reviewed by 3 uro-pathologists and sub-staged according to two clas-
siﬁcations: Metric sub-stage according to T1micro-invasive (T1m -
lamina propria invasion <0.5mm) vs. T1extensive-invasive (T1e - in-
vasion 0.5mm) and secondly, according to presence or absence of
muscularis mucosae invasion (MM - T1a vs. T1b). Prognostic value for
progression-free survival (PFS) and cancer-speciﬁc survival (CSS)
were analyzed for each system with a multivariable step-wise cox-
regression model. We corrected for sex, age, size (>3cm vs. 3 cm),
concomitant CIS, WHO 1973 and WHO 2004 grade.
RESULTS: Median follow-up was 5.9 (IQR 3.3-9.0) years.
Median age was 71 (IQR 15) years, 150 (25%) patients were female.
Concomitant CIS was found in 196 (33%) cases. Metric sub-staging
was possible in all cases. T1m was found in 213 (35%) tumors vs. 388
(65%) T1e. Based on MM invasion, 281 (47%) tumours were staged
T1a vs. 320 (53%) T1b. MM was identiﬁed at the invasion front in 466
(78%) tumors. During follow-up, progression (cT2 and/or N1 and/or
M1) was found in 148 (25%) patients and 95 (16%) patients died of BC.
On univariable analysis, both sub-staging systems were signiﬁcantly
associated with PFS and CSS. On multivariable analysis, metric (T1m/
e) sub-stage (T1e vs. T1m; HR 3.8, 95%CI 2.3-6.0, p<0.001) and WHO
1973 grade (G3 vs. G2; HR 1.8, 95%CI 1.2-2.7, p¼0.006) were prog-
nostic for progression. Independently associated with worse CSS were
T1e (HR 2.7, 95%CI 1.6-4.8), WHO 1973 G3 (HR 2.6, 95%CI 1.4-4.7,
p¼0.002), increasing age (HR 1.03, 95%CI 1.01-1.05, p¼0.002) and
tumor size >3 cm (HR 1.8, 95%CI 1.2-2.9, p¼0.008).
CONCLUSIONS: In this multi-center study, metric (T1m/e) sub-
stage proved a very reliable and strong prognosticator for progression
and cancer-speciﬁc survival. Our results suggest that metric T1 sub-
stage may aid in treatment decision-making between conservative
treatment and radical cystectomy for clinical T1-BC. T1a/b sub-stage
has inferior prognostic value and reproducibility. Ultimately, metric sub-
stage (T1m/e) may be incorporated in the TNM classiﬁcation system for
urinary BC.
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